Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedMar 05, 2026
DataAggregated Company Financials
Companies62
  • 7D0.05%
  • 3M-13.1%
  • 1Y-2.8%
  • YTD-13.3%

In the last week, the Life Sciences industry is up 1.6%, with IQVIA Holdings up 9.9%. Overall in the last year, the industry is flat. Looking forward, earnings are forecast to grow by 16% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 05 Mar 2026US$584.0bUS$147.8bUS$14.0b34.9x41.7x4x
Sat, 31 Jan 2026US$662.4bUS$147.0bUS$12.6b34x52.6x4.5x
Mon, 29 Dec 2025US$663.9bUS$145.8bUS$12.5b35.4x53.2x4.6x
Wed, 26 Nov 2025US$678.5bUS$145.6bUS$12.4b37.9x54.8x4.7x
Fri, 24 Oct 2025US$651.0bUS$145.2bUS$14.6b33.4x44.5x4.5x
Sun, 21 Sep 2025US$573.4bUS$144.3bUS$14.6b30.7x39.4x4x
Tue, 19 Aug 2025US$583.4bUS$144.2bUS$14.5b28.8x40.3x4x
Thu, 17 Jul 2025US$524.4bUS$142.9bUS$9.1b35.6x57.4x3.7x
Sat, 14 Jun 2025US$537.5bUS$142.9bUS$9.2b35.7x58.6x3.8x
Mon, 12 May 2025US$505.4bUS$142.8bUS$9.6b34.4x52.7x3.5x
Wed, 09 Apr 2025US$509.1bUS$142.5bUS$9.9b32x51.2x3.6x
Fri, 07 Mar 2025US$602.1bUS$143.1bUS$9.8b41.9x61.7x4.2x
Sun, 02 Feb 2025US$691.5bUS$143.0bUS$10.4b41.1x66.5x4.8x
Tue, 31 Dec 2024US$657.8bUS$142.4bUS$10.2b44.3x64.3x4.6x
Thu, 28 Nov 2024US$660.7bUS$142.4bUS$10.2b44.4x64.6x4.6x
Sat, 26 Oct 2024US$680.4bUS$142.0bUS$8.3b35.4x82.3x4.8x
Mon, 23 Sep 2024US$746.6bUS$141.8bUS$8.5b37.7x87.9x5.3x
Wed, 21 Aug 2024US$746.1bUS$141.9bUS$8.3b38.2x90x5.3x
Fri, 19 Jul 2024US$697.6bUS$141.2bUS$12.2b39.9x57.1x4.9x
Sun, 16 Jun 2024US$695.0bUS$141.3bUS$12.2b37.1x57.1x4.9x
Tue, 14 May 2024US$724.6bUS$141.5bUS$12.6b38.5x57.7x5.1x
Thu, 11 Apr 2024US$742.9bUS$142.0bUS$12.8b43.4x58.1x5.2x
Sat, 09 Mar 2024US$754.1bUS$142.1bUS$12.8b44.5x58.8x5.3x
Mon, 05 Feb 2024US$709.3bUS$147.5bUS$12.5b38.3x56.6x4.8x
Wed, 03 Jan 2024US$706.4bUS$153.9bUS$14.2b37.7x49.8x4.6x
Fri, 01 Dec 2023US$643.6bUS$153.8bUS$14.0b35x45.9x4.2x
Sun, 29 Oct 2023US$565.9bUS$153.8bUS$11.3b29.2x50.3x3.7x
Tue, 26 Sep 2023US$674.7bUS$154.6bUS$11.2b33.7x60.2x4.4x
Thu, 24 Aug 2023US$713.3bUS$154.6bUS$11.2b32.8x63.6x4.6x
Sat, 22 Jul 2023US$741.4bUS$155.5bUS$12.7b29.4x58.4x4.8x
Mon, 19 Jun 2023US$704.3bUS$152.4bUS$12.5b29.3x56.3x4.6x
Wed, 17 May 2023US$672.0bUS$152.4bUS$12.6b28.2x53.2x4.4x
Fri, 14 Apr 2023US$744.3bUS$154.6bUS$10.8b30.7x68.9x4.8x
Sun, 12 Mar 2023US$693.6bUS$154.5bUS$10.9b29.6x63.9x4.5x
Price to Earnings Ratio

63.9x


Total Market Cap: US$693.6bTotal Earnings: US$10.9bTotal Revenue: US$154.5bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 58.3x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 42.9x which is lower than its 3-year average PE of 58.4x.
  • The 3-year average PS ratio of 4.5x is higher than the industry's current PS ratio of 4.1x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 8.7% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-1.22%
Healthcare-1.04%
Life Sciences0.045%
Clinical Research and Equipment0.045%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
IQV IQVIA HoldingsUS$177.889.9%
+US$2.4b		-4.3%PE22x
ILMN IlluminaUS$128.975.8%
+US$1.1b		50.5%PE23.2x
MEDP Medpace HoldingsUS$465.866.3%
+US$788.4m		41.8%PE29.3x
ICLR ICONUS$110.209.1%
+US$702.5m		-40.9%PE14x
STVN Stevanato GroupUS$17.5014.4%
+US$600.6m		-8.2%PE29.2x

Latest News

STVN
US$17.50
Stevanato Group
7D
14.4%
1Y
-8.2%
ILMN
US$128.97
Illumina
7D
5.8%
1Y
50.5%

ILMN: Policy And Execution Risks Will Likely Limit Benefits From Supportive Consumables Pricing

Illumina's analyst price targets have seen a modest upward reset, with a slightly higher fair value estimate of $88.35. This is supported by Street research that highlights firmer competitive pricing in sequencing consumables and a range of recent target revisions tied to updated views on growth, margins, discount rates, and future P/E assumptions.
TEM
US$51.29
Tempus AI
7D
-4.5%
1Y
-3.3%
BIO
US$284.68
Bio-Rad Laboratories
7D
5.6%
1Y
9.3%

BIO: Share Repurchases And Margin Outlook Will Support Future Upside

Analysts have maintained their price target for Bio-Rad Laboratories at $375, citing updated assumptions that include slightly higher revenue, improved profit margins, and a lower future P/E multiple, which together support the unchanged assessment of fair value. What's in the News From October 1, 2025 to December 31, 2025, Bio-Rad Laboratories reported no additional share repurchases, with 0 shares bought for $0, under its existing buyback program (Key Developments).
CRL
US$179.58
Charles River Laboratories International
7D
7.2%
1Y
7.2%

CRL: Improving Book To Bill And 2026 Outlook Will Support Future Upside

The analyst fair value estimate for Charles River Laboratories International has been adjusted from $265 to about $255, as analysts recalibrated their models in response to recent changes in Street price targets, mixed fourth-quarter commentary, and revised expectations for growth, margins, and future price-to-earnings multiples. Analyst Commentary Recent Street research on Charles River Laboratories International has been active, with analysts revisiting their models around the latest fourth quarter update, new guidance, and changes in sector sentiment.
MEDP
US$465.86
Medpace Holdings
7D
6.3%
1Y
41.8%

MEDP: Efficiency And Biotech Exposure Will Support Margin Strength Going Forward

Analysts have lifted their implied fair value estimate for Medpace Holdings to $582 from $510, citing the company's efficiency as a contract research organization, stronger profit margin assumptions at 17.94%, and a higher future P/E of about 29.35x as key supports for the updated price targets across recent research. Analyst Commentary Recent research coverage has highlighted a generally constructive tone around Medpace, with several bullish analysts pointing to efficiency, exposure to biopharma clients, and margin profile as key parts of the equity story.
TMO
US$512.69
Thermo Fisher Scientific
7D
-0.2%
1Y
-2.2%
IQV
US$177.88
IQVIA Holdings
7D
9.9%
1Y
-4.3%
DHR
US$204.73
Danaher
7D
-2.3%
1Y
-2.8%
RGEN
US$125.84
Repligen
7D
-4.8%
1Y
-20.2%
A
US$120.54
Agilent Technologies
7D
-3.4%
1Y
-4.7%
AVTR
US$8.65
Avantor
7D
-4.5%
1Y
-45.1%
QGEN
US$46.88
Qiagen
7D
-3.6%
1Y
15.5%

QGEN: Possible Sale And Fresh Takeover Interest Will Drive Future Upside

Analysts have raised their blended price target for Qiagen by about $0.63 to $55.23. This reflects updated views on slightly different revenue growth, profit margin and future P/E assumptions after a mix of recent target increases and reductions across the Street.
MTD
US$1,286.66
Mettler-Toledo International
7D
-6.8%
1Y
2.3%

MTD: Buybacks And 2026 Sales Outlook Will Support Balanced Return Prospects

Analysts have maintained their $1,501 fair value estimate for Mettler-Toledo International while slightly adjusting underlying assumptions such as the discount rate, revenue growth, profit margin and future P/E. These changes reflect updated views on the company’s risk profile and earnings power without altering the overall price target.
ICLR
US$110.20
ICON
7D
9.1%
1Y
-40.9%

ICLR: Oncology Expansion And Accounting Overhang Are Expected To Reset Sentiment

Analysts have lowered their average price target on ICON from about $206 to roughly $155 as they factor in the ongoing internal accounting investigation, modestly softer growth and margin assumptions, a slightly higher discount rate, and a reduced future P/E multiple, even as some describe the recent share price weakness as creating a more compelling entry point. Analyst Commentary Recent research on ICON reflects a split view, with some analysts turning more constructive after the share price pullback while others remain cautious given the internal accounting investigation and softer growth and margin assumptions.
TXG
US$22.37
10x Genomics
7D
13.8%
1Y
104.7%

TXG: 2026 Academic Demand And Pricing Pressures Will Challenge Rich Sentiment

The analyst price target for 10x Genomics has increased from $14 to $17, as analysts factor in updated assumptions for faster revenue growth, slightly higher margins, and a higher future P/E multiple, despite ongoing caution around academic demand and single cell consumables. Analyst Commentary Recent street research on 10x Genomics points to a mixed setup, with price target changes reflecting both interest in the story and clear caution around execution, product mix, and end market trends.